Subtype-Specific Efficacy of Topical Streptococcus Postbiotic Emollient in Adolescents and Adults With Atopic Dermatitis and Comorbid Allergies: A Post-hoc Analysis of a Randomized, Double-Blind, Vehicle-Controlled Trial
In brief
Topical Streptococcus postbiotic clears skin in 55% without comorbid allergies versus 31% with
In a post-hoc analysis of 98 mild-to-moderate atopic dermatitis patients, the Streptococcus CX emollient achieved an Investigator's Global Assessment of clear or almost clear skin in 55% of those without allergic comorbidities compared with 31% of those who had them after eight weeks. Both groups improved skin scores, but only the comorbid group showed significant drops in systemic inflammatory markers, suggesting different mechanisms of benefit.
- Journal
- Allergy, asthma & immunology research (Q1)
- Published
- 1 July 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Jiseung Kang, Yesol Yim, Haeun Lee, So Min Kang, Dong-Geol Lee, Young Mok Heo, et al.
- PMID
- 42547472
- DOI
- 10.4168/aair.2026.18.4.611
Why clinicians should know about it
- Picked for Microbiology (medical) (top studies of the week, 9 August 2026).
Abstract
Topical Streptococcus postbiotic emollient (Strain CX) has shown efficacy for mild-to-moderate atopic dermatitis (AD) in a previous study; however, treatment responses according to allergic comorbidity status have not yet been explored. We conducted a post hoc analysis to evaluate the differential therapeutic effects of Strain CX in patients with AD stratified by the presence or absence of allergic comorbidities. This post hoc analysis was derived from a randomized, double-blind, vehicle-controlled trial (Clinical Research Information Service of South Korea, KCT0007876). A total of 98 patients with mild-to-moderate AD were stratified into placebo (n = 33), AD without allergic comorbidities (n = 29), and AD with allergic comorbidities (n = 36) groups. The primary outcomes were the Investigator's Global Assessment (IGA) score and the proportions of participants achieving 25% or 50% improvement in the Eczema Area and Severity Index (EASI), assessed at weeks 4 and 8. The secondary outcomes included a range of skin-related clinical and molecular measures, along with additional evaluations of serum inflammatory and allergic biomarkers as laboratory measures in the per-protocol analysis set. At week 8, 55.2% (16/29) of participants in the AD without allergic comorbidities group achieved an IGA score of 0 or 1 with ≥ 1 point reduction, compared to 30.6% (11/36) in the AD with allergic comorbidities group (P = 0.0272). Both Strain CX intervention groups showed significant improvements in skin parameters, including EASI, skin moisture, and transepidermal water loss. Notably, the AD with allergic comorbidities group solely exhibited significant reductions in systemic inflammatory markers, including sIL-2R (mean, -231.19; 95% confidence interval [CI], -378.82 to -83.57 pg/mL), CCL17 (-127.05; 95% CI, -251.80 to -2.31 pg/mL), and CCL22 (-578.40; 95% CI, -939.31 to -217.49 pg/mL). Clinical skin responses improved more in patients with AD without allergic comorbidities, while immunomodulatory benefits were observed in those with allergic comorbidities. These findings support patient stratification based on allergic comorbidity status for personalized Strain CX treatment strategies. Trial Registration: Clinical Research Information Service Identifier: KCT0007876.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.